Compare ALH & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALH | TVTX |
|---|---|---|
| Founded | 1908 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.3B |
| IPO Year | 2025 | 2013 |
| Metric | ALH | TVTX |
|---|---|---|
| Price | $25.47 | $62.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $30.88 | ★ $40.62 |
| AVG Volume (30 Days) | 479.5K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,709,237,000.00 | N/A |
| Revenue This Year | $7.42 | $44.76 |
| Revenue Next Year | $5.88 | $35.51 |
| P/E Ratio | $92.25 | ★ N/A |
| Revenue Growth | ★ 13.31 | N/A |
| 52 Week Low | $18.64 | $17.05 |
| 52 Week High | $28.23 | $66.24 |
| Indicator | ALH | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 62.67 |
| Support Level | $23.63 | $53.76 |
| Resistance Level | $26.26 | $66.24 |
| Average True Range (ATR) | 1.12 | 2.59 |
| MACD | -0.19 | 0.27 |
| Stochastic Oscillator | 10.53 | 67.32 |
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.